Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
L-Nutra Unveils Groundbreaking Study on Fasting Mimicking Diets (FMDs) and Chronic Lymphocytic Leukemia | ||
By: PR Newswire Association LLC. - 13 Feb 2024 | Back to overview list |
|
LOS ANGELES, Feb. 13, 2024 /PRNewswire/ -- L-Nutra Inc., premier nutri-technology company spearheading nutri-longevity science and nutri-medicine programs, is excited to announce the release of a pivotal study that explores the potential benefits of fasting mimicking diets (FMDs) in the treatment of chronic lymphocytic leukemia (CLL) in both mice and few human models. CLL is the most prevalent form of leukemia in Western countries, and this groundbreaking research suggests a promising avenue for more effective treatment options. The study focused on the synergistic effects of cyclic fasting combined with proteasome inhibitors, experimental medication showing early promise for the treatment of CLL. Researchers clinically assessed CLL mouse models as well as patients undergoing multiple consecutive cycles of the fasting mimicking diet (FMDs) and made several key observations:
"After multiple successful trials in breast cancer, this early research on CLL suggests that fasting mimicking diets (FMDs) could also play a crucial role in supporting the treatment of the condition in tandem with other therapies," said Dr. Joseph Antoun, CEO of L-Nutra Inc. "While more expansive clinical trials are needed, we are excited to continue exploring how a nourished fast with FMD amplifies the efficacy of proteasome inhibitors through combined Nutri-Medical therapy." The findings from this study open up potential new possibilities for CLL treatment strategies and food as medicine in general. The targeted effect of FMD on leukemic cells, combined with the synergistic impact of proteasome inhibitors, presents a promising avenue for more effective and personalized treatment approaches. L-Nutra Inc. remains committed to advancing the field of nutri-technology and personalized medicine, and this study marks a significant step forward in understanding the potential of FMDs in CLL treatment, offering hope for improved outcomes and enhanced quality of life for patients. About L-Nutra: View original content to download multimedia:https://www.prnewswire.com/news-releases/l-nutra-unveils-groundbreaking-study-on-fasting-mimicking-diets-fmds-and-chronic-lymphocytic-leukemia-302060330.html SOURCE L-Nutra Inc. |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |